OKUR — OnKure Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1637715 ·
Last close
$3.89
Market Cap
$157.14M
52W High
$4.79
52W Low
$3.70
ADV30
133,642
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -16,899,000 | -15,346,000 | 179,353,000 | 166,502,000 | 7,245,000 |
| Mar 2026 | 0 | — | -15,615,000 | -15,157,000 | 198,694,000 | 192,106,000 | 14,341,000 |
| Dec 2025 | 0 | — | -14,125,000 | -13,503,000 | 62,117,000 | 59,050,000 | 5,933,000 |
| Sep 2025 | 0 | — | -15,501,000 | -14,699,000 | 72,835,000 | 70,331,000 | 6,407,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,841,000
Investing CF
$-9,890,000
Financing CF
$140,859,000
CapEx
$-23,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.50
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-244,744,000
Inventory
—
Receivables
—
ST Investments
$9,884,000
EBIT TTM
$-60,708,000
Pretax Income TTM
$-58,705,000
Interest Exp TTM
$8,000
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -62,950,000 | -59,517,000 | 62,117,000 | 5,933,000 | — | -51,828,000 |
| Dec 2024 | 0 | -54,386,000 | -52,673,000 | 114,907,000 | 11,079,000 | — | -51,117,000 |
| Dec 2023 | 0 | -36,934,000 | -35,311,000 | 35,734,000 | 137,576,000 | — | -34,546,000 |
| Dec 2022 | 0 | -29,766,000 | -29,512,000 | 15,999,000 | 70,417,000 | — | -26,953,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc. | $154.56M | $1.16 | — |
| SPRC | SciSparc Ltd. | $153.67M | $6.66 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $150.84M | $13.20 | — |
| AARD | Aardvark Therapeutics, Inc. | $150.57M | $6.88 | — |
| MENS | Jyong Biotech Ltd. | $164.80M | $2.22 | — |
News headlines (Yahoo Finance, 1h cache)
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-08-04 20:05 · Yahoo
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
2026-07-15 17:02 · Yahoo
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
2026-07-02 12:00 · Yahoo
OnKure Therapeutics Reports First Quarter 2026 Financial Results
2026-05-05 20:05 · Yahoo
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
2026-04-16 13:18 · Yahoo
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
2026-03-27 12:00 · Yahoo
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-12 20:05 · Yahoo
Promising Penny Stocks To Watch In December 2025
2025-12-09 18:05 · Yahoo
3 Promising Penny Stocks With Market Caps Under $200M
2025-10-31 18:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.